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Background: The “seed and soil” hypothesis emphasizes the importance of interactions between tumor cells and their
microenvironment. CAFs (Cancer associated fibroblasts) are important components of the tumor microenvironment.
They were widely involved in cancer cells growth and metastasis. Fibroblasts may also play a role in inflammatory
disease. The phenotype conversion of fibroblasts in lung diseases has not been investigated previously. We hypothesized
that fibroblasts phenotypes may vary among different types of lung disease.
Methods: The study included six types of lung tissues, ranging from normal lung to lung adenocarcinoma with
lymphatic metastasis. Para-carcinoma tissues which were 2-cm-away from the tumor focus were also included in the
analysis. The expression of target proteins including alpha-SMA (smooth muscle actin), FAP (fibroblast activation protein),
vimentin, E-cadherin, and CK-19 (cytokeratin-19) were examined by immunohistochemistry. TGF-beta(transforming
growth factor) and Twist were detected simultaneously in all samples.
Results: A progressive increase in the levels of alpha-SMA, vimentin and CK-19 was observed in correlation to the degree
of malignancy from normal lung tissue to lung adenocarcinoma with lymphatic metastasis, whereas E-cadherin
expression showed the opposite trend. TGF-beta and Twist were detected in cancer tissues and inflammatory
pseudotumors. None of the proteins were detected in para-carcinoma tissues.
Conclusions: Fibroblast phenotypes varied according to the type and degree of lung malignancy and
fibroblasts phenotypic conversion occurs as a gradual process with specific spatiotemporal characteristics.
Similar fibroblast phenotypes in inflammatory diseases and cancer tissues suggested a correlation between
inflammation and cancer and implied a common mechanism underlying the formation of fibroblasts in
inflammatory diseases and lung cancer.
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The high degree of malignancy and heterogeneity of
cancer cells have led researchers to focus on the study of
malignant cells present in the epithelial compartment
[1]. The resistance of certain cancer cells to treatment
remains a critical issue [2]. In recent years, researchers
have discovered that tumor microenvironment also plays
an important role in tumor development. The inter-
action of the tumor microenvironment with cancer
cells make the matters more complicated [2-5]. Tumor
microenvironment may play a key role in tumor invasion
and can indirectly affect prognosis [2,6]. The development
of resistance against chemotherapeutic drugs brought* Correspondence: hxcheguowei@yahoo.com
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onment) is as important as seeds (cancer cells).
Specialized fibroblasts named cancer-associated fibro-
blasts (CAFs) are characterized by “cross-talk” with
cancer cells and have become novel targets for cancer
therapy [2,6,7]. CAFs can be formed through several
ways. The way named EMT (epithelial-mesenchymal
transition) was important. Studies have demonstrated
that in human breast and prostate cancer, TGF-β and
Twist secreted by tumor cells may induce EMT and pro-
mote the formation of CAFs [3,7-9]. CAFs express high
levels of α-SMA (smooth muscle actin) and vimentin
[3,10,11], whereas they are negative for cytokeratin and
E-cadherin [3,4,12]. Normal fibroblasts suppress tumor
genesis by inhibiting the proliferation of the adjacent
epithelium, CAFs play an opposite role [4].
Vicent S et al. [13] made a cross-species functional
characterization of mouse and human lung CAFs andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer cells in vivo by secretion of soluble factors that
directly stimulate the growth of tumor cells. They also
found that IL-6 (interleukin-6) secreted by CAFs pro-
moted cancer cells growth. Besides, CXCL-12/CXCR4
axis which existed between the cross-talk of CAFs and
non-small lung cancer cells was also contributed to the
proliferation of cancer cells [14]. Some proteins expressed
by CAFs such as matrix metalloproteinase (MMP)-2,
α-SMA, podoplanin and carbonic anhydrase (CA) IX may
correlated with the prognosis of lung cancer [15-17].
The phenotype conversion from normal fibroblasts to
CAF was associated with carcinogenesis but whether the
CAF phenotype varies among cancer tissues remain to
be elucidated. We hypothesized that TGF-β and Twist
participated in lung carcinogenesis. In previous studies,
the role of CAFs was investigated by assessing their
tissue-specific expression only in one type of human
cancer such as human prostate cancer or human breast
cancer [18,19]. We analyzed fibroblasts in a set of sam-
ples which including chronic inflammation, normal lung
tissue, atypical adenomatous hyperplasia, carcinoma in
situ, lung adenocarcinoma, and lung adenocarcinoma
with lymphatic metastasis. Para-carcinoma tissues were
collected from the relevant patients. A comparative ana-
lysis of these tissues was performed to examine the char-
acteristics of the phenotypic conversion of fibroblasts.
Methods
Patients
Patient samples were obtained from the department of
thoracic surgery of West China Hospital. The study was
approved by the West China Hospital Ethics Committee
(year 2013, No.32). All patients signed informed consent
forms. The distribution of patients was as follows: N
(pulmonary bulla) (n = 20), I (inflammatory pseudotumor)
(n = 22), H (atypical adenomatous hyperplasia)(n = 19), CIS
(carcinoma in situ) (n = 13) and CISJ (corresponding
adjacent tissues), A (lung adenocarcinoma without
lymph node metastasis) (n = 26) and AJ (corresponding
adjacent tissues), and AM (lung adenocarcinoma with
lymphatic metastasis) (n = 27) and AMJ (corresponding
adjacent tissues). None of the patients had received
chemotherapy or radiotherapy before surgery. Tissues
from patients with pulmonary bulla who were treated
surgically were used as controls because of the lack of
available healthy donor tissues. Besides, the CIS samples
were not as much as other samples for the reason that
cancer was very difficult to diagnose in an early stage.
Nearly all the CIS samples came from patients whose tu-
mors were found by regular medical examination. Unlike
other pathological stages of lung cancer, samples of CIS
(carcinoma in situ) of lung cancer is relatively hard to
found and the size of samples was very small. We couldnot obtained enough sections from a single patient.
Histological analyses of tissue samples were performed
independently by two pathologists who were blinded to




4.5 μm thick serial sections of formalin-fixed and paraffin-
embedded tissue samples were heated in citrate buffer
(0.01 M) for 30 min. Endogenous peroxidase activity was
quenched by incubation in 0.5% H2O2. Sections were then
blocked with serum and incubated with the respective pri-
mary antibodies at 4°C overnight. Primary antibodies and
their dilutions were as follows: mouse monoclonal anti
α-SMA (ZXGB BIO, Beijing, CHINA, 1:100); rabbit
polyclonal anti FAP (Assay Biotech, U.S.A. 1:200); mouse
monoclonal anti vimentin, mouse monoclonal anti-E-
cadherin, mouse monoclonal anti- CK-19, and rabbit poly-
clonal anti TGF-β (all obtained from ZXGB BIO, Beijing,
CHINA, and used at 1:100); and mouse monoclonal anti-
Twist (Santa Cruz Biotechnology, Dallas, U.S.A. 1:100).
Negative control sections were concurrently obtained from
each patient and incubated in PBS (0.01 M). Sections were
then incubated in the corresponding secondary antibody
(anti-mouse IgG and anti-rabbit IgG, both from ZSGB
BIO, Beijing, CHINA,1:200), then in the avidin biotin
complex reagent (ZSGB BIO, Beijing, CHINA,1:100) for
1 h at room temperature. Next, sections were visualized
by using 3, 3- diaminobenzidine (25 μL 3% H2O2 and
5 mL DAB) for 4 min and counterstained with nuclear fast
red for 2 min.
Immunohistochemistry analysis
For the markers expressed in cancer cells, high magnifi-
cation (40 × objective) was used to count the individual
cancer cells and a total of 200 cancer cells were scored
for each high-power field. For every section, five fields
were selected randomly. Normal alveolar epithelial cells
stained red by nuclear fast red were selected as negative
controls. According to Friedrichs et al. [18], a staining
index (SI, values 0, 1, 2, 3, 4, 6, and 9) was calculated as
a product of staining intensity (0–3) and the proportion of
positive cells (0% = 0, 1 − 10% = 1, 11 − 50% = 2, >50% = 3)
[18]. For CAFs, the SI was calculated as a product of
staining intensity (0–3) and the staining extent (0% = 0,
1 − 10% = 1, 11 − 50% = 2, >50% = 3).
Statistical analysis
The Wilcoxon rank sum test was used to compare the
marker status among the six disease types. Correlation
analyses between TGF-β and α-SMA, TGF-β and E-
cadherin, TGF-β and vimentin, Twist and α-SMA, Twist
and vimentin, and Twist and E-cadherin were performed
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The study included 127 patients (70 men and 57
women) with a mean age of 55 years (range: 18–74 years).
The presence of lymph node metastasis was confirmed by
intraoperative frozen section analysis and none of the pa-
tients had distant metastasis.
Fibroblasts phenotypic conversion characteristics
Detection of fibroblasts and epithelial markers
α-SMA was detected in benign and malignant tissues
and its expression was localized to blood vessels and air-
way ducts in N and H. Stromal cells were positive for
α-SMA in inflammatory pseudotumor as well as in all
three pathological stages of adenocarcinoma, although
with different staining intensity. α-SMA expression
was lower in CIS (SI ranged from 1 to 4 and the median
was 2) than in A (SI : 1 to 6, median was 4) (P = 0.026),
whereas AM (SI: 4 to 9, median was 6) showed higher ex-
pression than A (P = 0.009). Vimentin expression was
negative in N and H but positive in I. In the cancer
samples, Vimentin expression was higher in A (SI: 2
to 6, median was 3.5) than in CIS (SI: 0 to 4, median
was 2) (P = 0.017) and it was higher in AM (SI: 3 to 9,
median was 6) than in A (P = 0.022). In general, α-SMA
and vimentin expression increased gradually from N to
AM (Figure 1).
The epithelial marker E-cadherin was expressed at
high levels in the glandular epithelium of H. E-cadherinFigure 1 Expression of alpha-smooth muscle actin and vimentin in lu
actin (α-SMA) (a-f), vimentin (g-l)] were detected by immunohistochemistr
in the cytoplasm of CAFs. Magnification: 40× .staining intensity was lower in most CIS (SI: 0 to 3, me-
dian was 2) samples than in H (SI: 2 to 4, median was 3)
samples (P = 0.008), and it was higher in A (SI: 0 to 4,
median was 3) than in CIS (P = 0.827). E-cadherin ex-
pression was significantly lower in AM (SI: 0 to 1, me-
dian was 1) than in A (P < 0.001). CK-19 showed strong
staining in H and was expressed at higher levels in A
than in CIS (P = 0.003) and in AM (SI: 4–9 median
was 6) than in A (P = 0.035). Cancer epithelial cells
expressed more CK-19 in the samples from CIS to AM.
The expression of epithelial markers was negative in N
and in I (Figure 2).
Immunohistochemical detection of TGF-β, FAP, and Twist
The expression of TGF-β, FAP, and Twist was ana-
lyzed by IHC. Unlike the four markers which were de-
tected in interstitial cells (such as α-SMA and vimentin)
or the cancer cells membrane (such as CK-19), TGF-β
and FAP expression was detected in the cytoplasm of
cancer cells while twist was located in both cytoplasm
and nucleus. The three factors were expressed in I, CIS,
A, and AM, whereas N, H, but para-carcinoma tissues
were negatively stained (the results of N, I, and H were
not included in Figure 3). TGF-β was expressed at
higher levels in AM (SI: 3 to 9, median was 6) than in
A (SI: 2–9 median was 3.5) (P < 0.001). No statistical
significance was seen between CIS and A (P = 0.392).
On the other hand, Twist expression was seen in A
and AM. FAP expression was positive in the matrix
of cancer cells and negative in that of CAFs. FAP ex-
pression was detected in cancer cells of CIS, A and
AM, although the differences in expression levels among
CIS, A, and AM did not reach statistical significance
(Figures 3 and 4).ng tissues from N to AM. Fibroblast markers [alpha-smooth muscle
y. As shown in figure, both α-SMA and vimentin were stained positively
Figure 2 Expression of E-cadherin and cytokeratin-19 in lung tissues from N to AM. Epithelial markers [E-cadherin (a-f) and cytokeratin-19
(CK-19) (g-l)] were detected by immunohistochemistry. E-cadherin was located in cell membrane while CK-19 was located in cytoplasm.
Magnification: 40× .
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All the lung cancer samples (including CIS, A and AM,
totally 66 samples) expressed different levels of α-SMA,
vimentin, E-cadherin, Twist and TGF-β. We performed a
correlation analysis between TGF-β and α-SMA, TGF-βFigure 3 Expression of TGF-β, FAP and Twist in cancer tissues and pa
including TGF-β (a-f) and Twist (g-l) were detected by immunohistochemis
is not included in the figure. In these samples, TGF-β was located in cytopla
nuclei of cancer cells. FAP, a marker of CAFs, was expressed in the cytoplasm
This novel result may indicate that some cancer cell could secret FAP just lik
CAFs. However, TGF-β (b, d, f), Twist (h, j, l) or FAP (n, p, r) were negativelyand vimentin, TGF-β and E-cadherin, Twist and α-SMA,
Twist and E-cadherin and Twist and α-SMA in all the
cancer samples. A significant positive correlation was ob-
served between TGF-β and α-SMA and between TGF-β
and vimentin expression (Spearman’s rank correlationra-carcinoma tissues. Key factors in the cell signaling pathway
try. The expression of TGF-β and Twist in I (inflammation pseudotumor)
sm (a, c, e) and Twist (g, I, k) can be detected both in cytoplasm and
of cancer cells rather than in the stroma of cancer tissues (m, o, q).
e CAFs or these cancer cells secreting FAP may be a novel origin of
expressed by all of the para-carcinoma tissues. Magnification: 40×.
Figure 4 Statistical analysis of the relevant factors. The first row showed the correlation analysis between TGF-β and α-SMA (a), TGF-β and
E-cadherin (b), Twist and α-SMA (c) and Twist and E-cadherin (d) were performed in all the 66 lung cancer samples (including CIS, A, AM). Each
cycle in the figure represented one lung cancer sample. But some cycles were overlapped because these samples had a same score. α-SMA
expression was lower in CIS than in A (P = 0.026), whereas AM showed higher expression than A (P = 0.009) (Figure 4e). Vimentin expression was
negative in N and H but positive in I. In the cancer samples, Vimentin expression was higher in A than in CIS (P = 0.017) and it was higher in AM
than in A (P = 0.022) (Figure 4f). E-cadherin staining intensity was lower in most CIS than in H (P = 0.008), and it was higher in A than in CIS.
E-cadherin expression was significantly lower in AM than in A (P < 0.001) (Figure 4g). TGF-β expression followed a similar pattern than that of
α-SMA and vimentin, with positive expression in I, CIS, A, and AM. TGF-β was expressed at higher levels in AM than in A (P < 0.001). No statistical
significance was seen between CIS and A (P = 0.392) (Figure 4h). Twist expression was seen in I, A and AM (Figure 4i).
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spectively). A significant inverse correlation was observed
between TGF-β and E-cadherin (r = −0.449, p < 0.001).
However, a significant positive correlation was observed
between Twist and E-cadherin expression (r = 0.318,
p = 0.009). The relationship between Twist and α-SMA did
not reach statistical significance (p = 0.064) (Figure 4).
Spatial characteristics of the phenotypic conversion of
cancer-associated fibroblasts
The spatial pattern of the phenotypic conversion of
fibroblasts was examined by detecting marker protein
expression in para-carcinoma tissues using the same
methods. The results showed that adjacent tissues
stained negative for all the marker proteins analyzed
(Figure 3).
Discussion
In previous studies, co-implantation of tumor cells and
CAFs into immunodeficient mice induced tumor growth
at a faster rate than the implantation of cancer cells
alone or that of normal fibroblasts [19,20]. Cytokines se-
creted by CAFs may contribute to destroy the basement
membrane to facilitate tumor invasion and metastasis [21].
In the present study, we used six kinds of lung disease
to examine the spatiotemporal characteristics of thephenotypic conversion of fibroblasts. A mild, progressive
increasing trend in CAFs was observed from CIS, A to
AM tissues. This could be explained as follows: the ex-
pression of α-SMA and vimentin in the stroma were
increased from N to AM and both factors followed a
similar pattern of upregulation. The upregulation of
α-SMA promotes tumor formation and metastasis [22].
However, α-SMA expression was also positive in stro-
mal cells of I (inflammatory pseudotumor), similar to
that in tumors (P = 0.059). Increased TGF-β up-regulated
the expression of α-SMA in I and in lung cancer (r = 0.396,
p = 0.001). Vimentin, whose up-regulation is an indica-
tor of EMT, showed a similar staining pattern among
the different disease stages. Vimentin overexpression
has been detected in several types of tumors, including
lung adenocarcinoma, and its expression is correlated
with tumorigenesis, invasion, and metastasis [23-25]. In
addition to the markers of CAFs, we analyzed epithelial
markers, including E-cadherin and CK-19. The down-
regulation of these two epithelial markers accompanied
by the up-regulation of α-SMA and vimentin is considered
a key process associated with EMT [26,27]. E-cadherin
may play a role in suppressing tumor metastasis. Liu et al.
showed that the impaired integrity of the E-cadherin-
catenin system is responsible for the reduced or even nega-
tive expression of E-cadherin [28,29]. In addition, Twist
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pression. CK-19 is frequently detected in serum as the
fragment CYFRA −21 [30-32], and its expression in par-
enchyma cells is consistent with the results of the present
study. The upregulation of CK-19 expression in cancer
epithelial cells is associated with tumor invasion and
lymphatic metastasis [33-35], which is also consistent
with our results. However, the association between high
CK-19 reactivity and cancer and its role in metastasis
should be further investigated.
TGF-β, Twist and FAP were expressed at various levels
in the different tumor tissues from CIS to AM. TGF-β is
a multifunctional protein that induces fibrosis of lung
tissue, tumor invasion, and metastasis by promoting EMT,
and EMT takes an active part in fibrotic disease, as well as
in cancer cell movement and invasion [36-39].
The involvement of TGF-β in EMT may require its as-
sociation with Smad and Snail signaling or the activity of
the Ras pathway; however, activated Smad or H-Ras may
not be sufficient for the EMT process without the pres-
ence of TGF-β [40]. Ronnov-Jessen et al. suggested that
TGF-β is the only factor required for the conversion of
normal fibroblasts into CAFs [41]. Furthermore, Fibro-
blasts secrete TGF-β to remain active and promote their
own proliferation [3]. The transcription factor Twist
exerts a similar function to that of TGF-β [8,9,42,43],
and its upregulation is correlated with alterations in E-
cadherin expression [44]. However, the present study
showed the opposite results. A significant positive rela-
tionship was observed between Twist and E-cadherin
expression (r = 0.318, p = 0.009). Comparison of Twist
and E-cadherin expression between CIS and A showed a
negative correlation. These results indicated a discordant
pattern of expression of Twist, particularly in association
with the process of tumor metastasis, which led us to
hypothesize that Twist expression may be an indicator
of metastasis in lung adenocarcinoma.
Among the six types of tissues, I (inflammatory pseu-
dotumor) exhibited an abnormal pattern of immuno-
staining and was positive for α-SMA, vimentin, as well
as TGF-β (Figure 1). TGF-β is among the factors se-
creted during the inflammatory response [45] and may
promote the upregulation of α-SMA in response to in-
flammation. In inflammatory diseases such as Hepatitis
B and inflammatory bowel disease, malignant transform-
ation may lead to the development of hepatocellular
carcinoma and colorectal carcinoma, respectively. The
results of the present study suggest that benign inflam-
matory diseases may progress and develop into malig-
nant lung tumors.
In addition to α-SMA and vimentin, FAP, is also con-
sidered to be a specific marker for CAFs [46]. However,
our results showed that FAP was expressed in the cyto-
plasm of cancer cells rather than in the cytoplasm ofCAFs, and no statistically significant differences were de-
tected among CIS, A, and AM tissues. TGF-β expression
was also localized to the matrix of cancer cells, which
was not consistent with the results reported by Xing
et al. These two novel phenomena revealed by our find-
ings indicated that cancer cells might have a similar
function as CAFs and CAFs may not originate exclu-
sively from normal epithelial cells but may also be derived
from mutant epithelial cells, including cancer cells [2].
Both lung inflammatory pseudotumor and atypical ad-
enomatous hyperplasia might have something to do with
malignant lung diseases. Lung inflammatory pseudotu-
mor, whose etiology was still unknown, was a relative
rare benign lung tumor and account for about 0.7% of
primary pulmonary and bronchial tumors. [47] This be-
nign lung disease had malignant biological behavior in-
cluding locally invasive, aggressiveness and unfavorable
evolution which needed extensive pulmonary resection
to prevent local recurrence. Though no detail data about
the incidence and the probability that the patients with
lung cancer resulting from inflammatory pseudotumor
was provided, it was better to have this lesion resected
as early as possible [47]. Atypical adenomatous hyperpla-
sia may be the adenoma in an adenoma–carcinoma se-
quence in the lung periphery, leading to the development
of adenocarcinoma. Atypical adenomatous hyperplasia
had a low morbidity of 4.4% and 9.6% [48,49]. The inci-
dence was higher in patients bearing lung cancer espe-
cially in those with lung adenocarcinoma (15.6% vs 23.2%)
[50]. It had been demonstrated that atypical adenomatous
hyperplasia might result in lung squamous carcinoma.
Whether or not it would result in lung adenocarcinoma
still need more research [51].
The present study analyzed a series of lung diseases
simultaneously. We used longitudinal and cross-sectional
analyses to investigate phenotypic variations in fibro-
blasts. While previous studies compared cancer cells to
normal tissues in a static manner, our research reflected
the dynamic changing process of fibroblasts. In addition
to their role in promoting tumor invasion and metastasis,
their function in providing a microenvironment for
tumor cells similar to that of soils for seeds, fibroblasts
were shown to undergo phenotypic conversion in a spe-
cific spatiotemporal pattern. Considering the progressive
emergence of drug resistant phenotypes in cancer, our re-
sults suggest that activated fibroblasts may represent a
potential target for molecular targeted therapy in lung
cancer and provide a correlation between inflammatory
diseases and cancer. The limitations of the present study
were mainly derived from the lack of sample. Samples of
CIS were specially limited for it was very hard to diag-
nose cancer at very early stage. The differences between
our results and those of previous studies could be related
to the small number of samples included in the analysis.
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cells, which could lead to the differential expression of
the factors analyzed.
In the present study, we detected seven types of fac-
tors. TGF-β showed a positive role in EMT and facili-
tated the generation of CAFs. Because Twist showed a
similar function, we were unable to determine whether
one of the factors plays a key role or if both are critical
for EMT. If both TGF-β and Twist are essential for
EMT, assessment of the potential cross-talk between the
two factors would be important. However, IHC is insuffi-
cient to examine this issue, which we plan to address
using different methods in future studies.
Conclusions
Fibroblast phenotypes vary according to the type and de-
gree of lung diseases and their phenotypic conversion
occurs as a gradual process with specific spatiotemporal
characteristics. Similar fibroblast phenotypes in inflam-
matory diseases and cancer tissues suggested a correl-
ation between these two disease types and a common
mechanism underlying the formation of fibroblasts in in-
flammatory diseases and lung cancer. The present study
want to provide a new idea about cancer therapy.
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